Company Description
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer.
The company’s lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells.
TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D.
Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jul 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Thomas Fitzgerald |
Contact Details
Address: 6 Liberty Square, Suite 2382 Boston, Massachusetts 02109 United States | |
| Phone | 857 837 3099 |
| Website | transcodetherapeutics.com |
Stock Details
| Ticker Symbol | RNAZ |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001829635 |
| CUSIP Number | 89357L105 |
| ISIN Number | US89357L3033 |
| Employer ID | 81-1065054 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas A. Fitzgerald M.B.A. | Interim Chief Executive Officer, Chief Financial Officer, President, Vice President of Administration and Director |
| Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. | Executive Chairman of the Board |
| Dr. Zdravka Medarova Ph.D. | Co-Founder and Chief Scientific Officer |
| Dr. Anna Moore Ph.D. | Co-Founder, Scientific Advisor and Member of Scientific Advisory Board |
| Susan Duggan M.B.A., R.N. | Senior Vice President of Operations |
| Dr. Daniel R. Vlock M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 21, 2025 | 8-K | Current Report |
| Apr 16, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 15, 2025 | 10-K | Annual Report |
| Apr 11, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 31, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 424B5 | Filing |
| Mar 20, 2025 | SCHEDULE 13D | Filing |